Creating a World Where Everyone with ALS Lives
Dear Friends and Colleagues,

We all hoped we would finally return to normal in 2021. But despite the ongoing challenges caused by the COVID-19 pandemic, I am amazed at what Target ALS has continued to accomplish. We have forged ahead with our funding for breakthrough research; established a one-of-a-kind scientific core; nurtured important new alliances, including across related neurodegenerative diseases; and helped bring more attention to the fight against ALS.

All these encouraging signs came in a year in which I was given a likely ALS diagnosis. As a result, I’ve pulled back from many of my responsibilities so that I can focus on two life-affirming activities: spending more time with friends and family and helping advance ALS research.

We are all working together to create a world in which everyone with an ALS diagnosis lives a long, high-quality life. Thank you for bringing us to a place where the achievement of these goals may be possible.

Yours in this fight against ALS,

Daniel L. Doctoroff
Founder
Dear Target ALS Community,

It has been a privilege to work this past year with extraordinary scientists from academia and the pharma/biotech industry, executives from for-profit and nonprofit organizations, and especially all the supporters who have helped Target ALS change the landscape of ALS research.

As you review our Annual Report 2021, please pay special attention to these milestone accomplishments:

• We forged a partnership with Gates Ventures/Alzheimer’s Drug Discovery Foundation (ADDF), which will fund collaborative projects focused on biomarkers applicable to ALS, Alzheimer’s disease (AD), and frontotemporal dementia (FTD). Recipient grantees were announced recently.

• We continued our partnership with The Association for Frontotemporal Degeneration (AFTD). One of the co-funded projects has already led to a clinical trial.

• We funded five projects to test novel drug targets in animal models of ALS through our in vivo target validation core.

• Our Longitudinal Biofluid Core began active case recruitment to collect biosamples from ALS and control cases.

As we move closer to 2023 and beyond, Dan, the Target ALS team, and I have redoubled our efforts and focused on our short- and long-term ambitions. We plan to build on our successes and accelerate the work of Target ALS, introducing seven areas of new and increased funding to catalyze our collaborative teams even more efficiently and broadly. To those of you who have helped in the past or are just being introduced to Target ALS, we can’t express our appreciation enough and hope you will be further inspired to participate as you read on.

Thank you,
Manish Raisinghani, MBBS, PhD
Chief Executive Officer
**Foundation Advisors**

**Chris Henderson, PhD**  
Chief Advisor, Target ALS  
Senior Vice President, Head of Research, Biogen

**Leonard Petrucelli, PhD**  
Chief Scientific Advisor, Target ALS  
Professor of Neuroscience, Mayo Clinic

**Board Members**

**Daniel L. Doctoroff**  
Founder and Board Chair, Target ALS  
Former Deputy Mayor of New York City for Economic Development and Rebuilding  
Former Founder and Chief Executive Officer, Sidewalk Labs

**John Dunlop, PhD**  
Chief Scientific Officer, Neumora Therapeutics

**Zach Hall, PhD**  
Chair, Target ALS COI Committee  
Former Director, NIH NINDS

**Richard Hargreaves, PhD**  
Senior Vice President, Bristol-Myers Squibb

**Carole Ho, MD**  
Chief Medical Officer and Head of Development, Denali Therapeutics

**Story Landis, PhD**  
Former Director, NIH NINDS  
Board Liaison, Independent Review Committee

**Mike Poole, MD**  
Senior Advisor, Neumora Therapeutics

**Sarah I. Sheikh, BM BCh, MSc, MRCP**  
Senior Vice President, Neuroscience Takeda

**Stacie Weninger, PhD**  
President, F-Prime Biomedical Research Initiative
Independent Review Committee

Robert Miller, PhD  
Chair, Target ALS IRC  
Vivian Gill Distinguished Research Professor; Vice Dean for Research and Academic Affairs, Professor of Anatomy and Cell Biology, George Washington University

Michael Ahlijianian, PhD  
Chief Scientific Officer, Pinteon Therapeutics

Manzoor Bhat, PhD, MS  
Vice Dean for Research (Interim), Professor and Chair at UT Health San Antonio

Elizabeth D. Buttermore, PhD  
Director of Translational In Vitro Models  
Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital

Moses Chao, PhD  
Professor, Department of Neuroscience and Physiology, New York University

Merit Cudkowicz, MD  
Chief, Neurology Department; Director, Sean M. Healey and AMG Center for ALS  
Julianne Born Professor of Neurology, Harvard Medical School

Michela Deleidi, MD, PhD  
Helmholtz Group Leader, DZNE German Center for Neurodegenerative Diseases  
University of Tübingen

Biljana Djukic, PhD  
Translational Medicine and Early Development Lead, Neurology and Rare Diseases, Sanofi

Fanny Elahi, MD, PhD  
Asst. Professor of Neurology and Neuroscience; Assistant Professor of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai

Lisa Ellerby, PhD  
Professor, Buck Institute

Kenneth Fischbeck, MD  
NIH Distinguished Investigator, NIH NINDS

Judith Frydman, PhD  
Donald Kennedy Chair, School of Humanities and Sciences and Professor of Genetics  
Frydman Lab, Stanford University

Jonathan Glass, MD  
Professor of Neurology and Pathology, Director of the Emory ALS Center, Emory University

Orla Hardiman, MD, FRCPI  
Professor of Neurology/Head of Academic, Clinical Medicine Trinity College of Dublin

Erika Holzbaur, PhD  
Professor of Physiology

Aimee Kao, MD, PhD  
John Douglas French Foundation Endowed Professor; Director, Medical Scientist Training Program, Memory and Aging Center, University of California, San Francisco

Zaven Kaprielian, PhD  
Chief Scientific Officer, Remix Therapeutics

Holly Kordasiewicz, PhD  
Vice President, Neurology Research Ionis Pharmaceuticals

Jim Kupiec, MD  
Chief Clinical Development Officer, Cassava Sciences

Claire Le Pichon, PhD  
Principal Investigator NIH Unit on the Development of Neurodegeneration

Pamela Maher, PhD  
Research Professor, Cellular Neurobiology Laboratory, Salk Institute

Robert Mays, PhD  
Executive Vice President of Regenerative Medicine and Head of Neuroscience Programs, Athersys

Alexander McCampbell, PhD  
Global Head of Neuroscience & Rare Disease Research at Pharma Research & Early Development Roche
Independent Review Committee (cont)

Jere Meredith Jr., PhD
Senior Director Neuroscience, Arvinas

Richard Olson, PhD
Director, Small Molecule Drug Discovery, Bristol-Myers Squibb

Manuela Polydoro, PhD
Vice President, Head of Translational Medicine, Muna Therapeutics

Mahendra Rao, MD, PhD
Chief Executive Officer, Implant Therapeutics

Rajiv Ratan, MD, PhD
Chief Executive Officer, Burke Institute and Associate Dean, Weill Medical College at Cornell University

Ian Reynolds, PhD
President, YaghPenn Consulting

Tracy Saxton, PhD
Managing Director, Saxton Biopharma Consulting LLC

Rob Scannevin, PhD
Chief Scientific Officer, Verge Genomics

Eric Schaeffer, PhD
Chief Scientific Officer, Paros Bio

Kimberly Scearce-Levie, PhD
Vice President, Translational Sciences Denali Therapeutics

Holly Soares, PhD
Head of Precision Medicine, Vice President, Pfizer

Ajay Verma, MD, PhD

Frank Walsh, PhD
Founder and Chief Executive Officer, Ossianix

Andrew Wood, PhD
Vice President, Clinical Neuroimaging Research, CHDI

Staff

Manish Raisinghani, MBBS, PhD
Chief Executive Officer

Kenneth Devaney
Chief Operations Officer

Steve Schonberg
Director of Communications

Burhan Siddiqui
Accounting and Financial Systems Manager
By the Numbers

Forging New Partnerships

As we advance our efforts toward developing therapies for ALS, one thing is clear: we must continue to engage new talents and technologies working on ALS.

That is why we are collaborating with partners working on related neurodegenerative disorders like AD and FTD. We aim to expand the breadth of talent and technologies applied to finding potential treatments and biomarkers for these diseases that often share genetic causes or biological mechanisms. Partnerships we have forged with Gates Ventures, ADDF and AFTD, among others are helping us achieve this goal.

Key Statistics

In partnership with Gates Ventures and the ADDF, we dedicated $2.4 million in funding to researchers investigating biomarkers useful for ALS and related neurodegenerative diseases like AD and FTD.

We established a one-of-a-kind Longitudinal Biofluid Core that will, for the first time, allow access to biofluid samples collected over the course of ALS, complete with associated de-identified clinical and demographic information as well as genomic data sets. These critically needed samples will be available to researchers in 2023.

Our partnership with AFTD, announced in 2019, resulted in funding for six pharma/biotech-led projects working to find treatments or biomarkers for both ALS and FTD. One of these projects has already resulted in the launch of a clinical trial for ALS (in 2021).

We also funded five new projects to test new drug targets, utilizing an animal model for ALS. A beneficial effect of a drug in an animal model of the disease is a key step in its progress toward the clinic.
Groundbreaking Partnership

Working with Gates Ventures and The Alzheimer’s Drug Discovery Foundation to Accelerate Biomarker Discovery and Development
Groundbreaking Partnership

In December 2021, Target ALS announced an innovative new partnership with Gates Ventures and the ADDF focused on identifying and developing biomarkers for ALS, along with other neurodegenerative diseases like AD and FTD.

The goal is to encourage cross-pollination of ideas across different research communities. Biomarkers can help diagnose neurodegenerative diseases earlier, reliably track their progression, and assess the effects of new drugs, leading to more efficient clinical trials.

The partnership funds four biomarker-focused collaborative research projects led by a researcher from a pharma/biotech company in collaboration with academic scientists.
Groundbreaking Partnership

Partnership with the Association for Frontotemporal Degeneration Results in New Clinical Trial

Capping a highly successful two-year partnership with AFTD, Target ALS has co-funded six research groups doing critical work in ALS and FTD. One has already launched a clinical trial, and the other five are moving forward despite challenges posed by the pandemic.

Because ALS and FTD share overlapping genetic causes and mechanisms, the partnership incentivized pharma/biotech scientist-led collaborative projects to work on therapeutic approaches or biomarkers applicable to both ALS and FTD.
Update on Target ALS Diagnosis Initiative

The Target ALS Diagnosis Initiative, launched in 2020, is funding research and creating scientific resources to discover and develop critically needed biomarkers.

Under this initiative, we funded four biomarker-focused collaborative projects led by a pharma/biotech-based scientist. The projects have, by now, completed the first year of their funding period.

We also funded precompetitive biomarker projects focused on understanding the forms of TDP-43 and developing new tests to measure its levels present in the cerebrospinal fluid of ALS patients. The data and tools generated from these projects will be shared with the ALS research community worldwide.

TDP-43 pathology is the most common neuropathologic hallmark in ALS, occurring in greater than 90 percent of all cases. It is also a common neuropathologic feature in other neurodegenerative diseases, including AD and FTD.

With Target ALS serving as the hub of this collaboration, the project has brought together a cross-sectoral group that includes 14 pharma/biotech groups and a panel of 10 academic experts and six nonprofit foundations. Members of this initiative have worked together over the past two years to formulate and launch the two TDP-43-focused projects.
Target ALS Launches Longitudinal Biofluid Core

The suite of our scientific cores continues to expand to provide access to critically needed research tools and resources.
Target ALS has successfully launched a Longitudinal Biofluid Core and established a new inventory management system across the Biofluid and Postmortem Tissue Cores, which will significantly increase the efficiency of sample management and distribution.

Access to longitudinal biofluid samples—cerebrospinal fluid, blood, and urine—has been a long-standing barrier to the advance of ALS research. Donated by ALS patients over the course of their disease and by healthy individuals (control cases), these samples offer unique insights into the pathogenic evolution of ALS over time. They will now be available to researchers on an expedited basis beginning in 2023 and will help galvanize biomarker discovery and development for ALS worldwide.

Over the past nine years, Target ALS has successfully launched seven scientific cores that provide no-strings-attached access to crucial research tools and resources for the worldwide ALS research community. Over 500 ALS projects worldwide have used these cores.

Projects to create new animal models for ALS have progressed significantly. A mouse model for C9orf72 ALS is in the final phase of evaluation. Projects to create mice that carry genetic mutation on the TDP-43 gene, which would potentially help test new drug targets for familial and sporadic ALS, are also in progress. Evaluation of one of the TDP-43 mouse models to determine features of ALS is currently underway.
Annual Meeting

Bringing together the diverse constituencies of the worldwide ALS research community is an important part of our work to advance ALS drug discovery and development. Attendees immerse in cutting edge ALS research and network, while forging new collaborations across academia and the pharma/biotech industry, venture capital and non-profits.

Key Statistics

- **Over 700** total attendees
- Newly implemented hybrid option enabled a broader cross-section of the worldwide community to participate
- **100+** networking meetings occurred
A Star-Studded “Becca”

To honor the life and legacy of Broadway legend Rebecca Luker, Target ALS presented a one-night-only musical tribute called “Becca,” featuring top talent from Broadway, TV, film, and beyond. The concert was partially sponsored by Mitsubishi Tanabe Pharma America (MTPA) and raised more than $150,000 in immediate funds for ALS projects.

Presented online in May 2021, the concert featured Tony recipients and nominees Kristin Chenoweth, Laura Benanti, and Judy Kuhn. Many remembered performing alongside Rebecca in musicals, including *Mary Poppins*, *The Music Man*, and *The Sound of Music*.

As a result of the concert’s success, we created a special awards series in Rebecca’s honor—the Rebecca Luker Courage Awards—to commemorate individuals making a remarkable impact in the fight against ALS. This award was created in partnership with MTPA. Winners include leading researchers, ALS advocates, and a generous philanthropist who have all contributed their time, energy, and passion to the fight against the disease.
Financials

**TALS**

- Contribution: 60%
- Grant Revenue: 34%
- Other Revenue: 1%
- Special Events: 5%

**TALS**

- Research and Program: 79%
- Fundraising: 9%
- General and Administrative Costs: 12%
- Special Events: 5%
Target ALS would like to thank its wide range of donors whose generous contributions help make our work possible.

Jeffrey Altman
Michele Jean Anderson
Anonymous
Mark Bauernhuber
Elizabeth Bennett
Lindsey Boylan and LeRoy Kim
Broadway Cares
Diane Chesnut
Robert Collins
Peter Coombe and Betty Chen
Scott Corwin
Daniel and Alisa Doctoroff
Alan Eustace
Barbara Freitag
Jesse Furman and Ariela Dubler
Martha Giacobassi
Zach W. Hall and Julie Ann Giacobassi
Rachel Neumark Herlands
Heron Family Foundation
Clark Hoyt
Sally Huxley
Ioana Ivan
The Jaquith Family Foundation
Samuel Katz
Marcia Kunstel
Marcia A. Kunstel and Joseph Albright
Jim Levine
John Logan
Susanne and Jeff Lyons
Thomas S. Maentz
Rose Novak Fund
Charles John O’Byrne
Kevin O’Meara
Max Oglesbee
Samuel Palmisano
Dahlia Prager
Prem Ramaswami
Sarah Rebell
Richard Rieger
Judith Rubin
Judy Rutkowski
Julie and Michael Salinger
Daniel Sapadin
Mary Speyer
Mike L. Tennican
Stephen M. Unfried
Matthew Winkler
Howard Wolfson
Bruce Yannett

THANK YOU!